Selected research
Industry Research
Anti-Neoplastic Pharmaceutical Agent Industry Research Report 2026
Market perspective
The global Anti-Neoplastic Pharmaceutical Agent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Anti-Neoplastic Pharmaceutical Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Anti-Neoplastic Pharmaceutical Agent market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Anti-Neoplastic Pharmaceutical Agent market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Anti-Neoplastic Pharmaceutical Agent include Innovent, Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer and Hengrui Medicine, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Anti-Neoplastic Pharmaceutical Agent market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Anti-Neoplastic Pharmaceutical Agent.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-Neoplastic Pharmaceutical Agent Market by Company
Innovent
Takeda
Johnson & Johnson
Novartis
Merck KGaA
Roche
Eli Lilly
Pfizer
Hengrui Medicine
GSK
Bristol-Myers Squibb
Amgen
AbbVie
AstraZeneca
Seagen
Regeneron
Ono Pharmaceutical
Merck & Co
Gilead Sciences
Exelixis
Anti-Neoplastic Pharmaceutical Agent Segment by Type
Cancer Immunotherapy
Chemotherapy
Targeted Therapy
Other
Anti-Neoplastic Pharmaceutical Agent Segment by Application
Blood-related Cancer
Breast Cancer
Prostate Cancer
Lung Cancer
Other
Anti-Neoplastic Pharmaceutical Agent Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Neoplastic Pharmaceutical Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Neoplastic Pharmaceutical Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Neoplastic Pharmaceutical Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Anti-Neoplastic Pharmaceutical Agent companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cancer Immunotherapy
- Chemotherapy
- Targeted Therapy
- Other
Applications
- Blood-related Cancer
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Other
Companies covered
- Innovent
- Takeda
- Johnson & Johnson
- Novartis
- Merck KGaA
- Roche
- Eli Lilly
- Pfizer
- Hengrui Medicine
- GSK
- Bristol-Myers Squibb
- Amgen
- AbbVie
- AstraZeneca
- Seagen
- Regeneron
- Ono Pharmaceutical
- Merck & Co
- Gilead Sciences
- Exelixis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Anti-Neoplastic Pharmaceutical Agent by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cancer Immunotherapy
- 2.2.3 Chemotherapy
- 2.2.4 Targeted Therapy
- 2.2.5 Other
- 2.3 Anti-Neoplastic Pharmaceutical Agent by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Blood-related Cancer
- 2.3.3 Breast Cancer
- 2.3.4 Prostate Cancer
- 2.3.5 Lung Cancer
- 2.3.6 Other
- 2.4 Assumptions and Limitations
3 Anti-Neoplastic Pharmaceutical Agent Breakdown Data by Type
- 3.1 Global Anti-Neoplastic Pharmaceutical Agent Historic Market Size by Type (2021-2026)
- 3.2 Global Anti-Neoplastic Pharmaceutical Agent Forecasted Market Size by Type (2027-2032)
4 Anti-Neoplastic Pharmaceutical Agent Breakdown Data by Application
- 4.1 Global Anti-Neoplastic Pharmaceutical Agent Historic Market Size by Application (2021-2026)
- 4.2 Global Anti-Neoplastic Pharmaceutical Agent Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Anti-Neoplastic Pharmaceutical Agent Market Perspective (2021-2032)
- 5.2 Global Anti-Neoplastic Pharmaceutical Agent Growth Trends by Region
- 5.2.1 Global Anti-Neoplastic Pharmaceutical Agent Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Anti-Neoplastic Pharmaceutical Agent Historic Market Size by Region (2021-2026)
- 5.2.3 Anti-Neoplastic Pharmaceutical Agent Forecasted Market Size by Region (2027-2032)
- 5.3 Anti-Neoplastic Pharmaceutical Agent Market Dynamics
- 5.3.1 Anti-Neoplastic Pharmaceutical Agent Industry Trends
- 5.3.2 Anti-Neoplastic Pharmaceutical Agent Market Drivers
- 5.3.3 Anti-Neoplastic Pharmaceutical Agent Market Challenges
- 5.3.4 Anti-Neoplastic Pharmaceutical Agent Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Anti-Neoplastic Pharmaceutical Agent Players by Revenue
- 6.1.1 Global Top Anti-Neoplastic Pharmaceutical Agent Players by Revenue (2021-2026)
- 6.1.2 Global Anti-Neoplastic Pharmaceutical Agent Revenue Market Share by Players (2021-2026)
- 6.2 Global Anti-Neoplastic Pharmaceutical Agent Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Anti-Neoplastic Pharmaceutical Agent Head Office and Area Served
- 6.4 Global Anti-Neoplastic Pharmaceutical Agent Players, Product Type & Application
- 6.5 Global Anti-Neoplastic Pharmaceutical Agent Manufacturers Established Date
- 6.6 Global Anti-Neoplastic Pharmaceutical Agent Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Anti-Neoplastic Pharmaceutical Agent Market Size (2021-2032)
- 7.2 North America Anti-Neoplastic Pharmaceutical Agent Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
- 7.4 North America Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Anti-Neoplastic Pharmaceutical Agent Market Size (2021-2032)
- 8.2 Europe Anti-Neoplastic Pharmaceutical Agent Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
- 8.4 Europe Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size (2021-2032)
- 9.2 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Anti-Neoplastic Pharmaceutical Agent Market Size (2021-2032)
- 10.2 South America Anti-Neoplastic Pharmaceutical Agent Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
- 10.4 South America Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size (2021-2032)
- 11.2 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Anti-Neoplastic Pharmaceutical Agent Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Innovent
- 12.1.1 Innovent Company Information
- 12.1.2 Innovent Business Overview
- 12.1.3 Innovent Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.1.4 Innovent Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.1.5 Innovent Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.2.4 Takeda Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 Johnson & Johnson
- 12.3.1 Johnson & Johnson Company Information
- 12.3.2 Johnson & Johnson Business Overview
- 12.3.3 Johnson & Johnson Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.3.4 Johnson & Johnson Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.3.5 Johnson & Johnson Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.4.4 Novartis Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Merck KGaA
- 12.5.1 Merck KGaA Company Information
- 12.5.2 Merck KGaA Business Overview
- 12.5.3 Merck KGaA Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.5.4 Merck KGaA Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.5.5 Merck KGaA Recent Developments
- 12.6 Roche
- 12.6.1 Roche Company Information
- 12.6.2 Roche Business Overview
- 12.6.3 Roche Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.6.4 Roche Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.6.5 Roche Recent Developments
- 12.7 Eli Lilly
- 12.7.1 Eli Lilly Company Information
- 12.7.2 Eli Lilly Business Overview
- 12.7.3 Eli Lilly Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.7.4 Eli Lilly Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.7.5 Eli Lilly Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.8.4 Pfizer Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 Hengrui Medicine
- 12.9.1 Hengrui Medicine Company Information
- 12.9.2 Hengrui Medicine Business Overview
- 12.9.3 Hengrui Medicine Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.9.4 Hengrui Medicine Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.9.5 Hengrui Medicine Recent Developments
- 12.10 GSK
- 12.10.1 GSK Company Information
- 12.10.2 GSK Business Overview
- 12.10.3 GSK Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.10.4 GSK Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.10.5 GSK Recent Developments
- 12.11 Bristol-Myers Squibb
- 12.11.1 Bristol-Myers Squibb Company Information
- 12.11.2 Bristol-Myers Squibb Business Overview
- 12.11.3 Bristol-Myers Squibb Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.11.4 Bristol-Myers Squibb Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.11.5 Bristol-Myers Squibb Recent Developments
- 12.12 Amgen
- 12.12.1 Amgen Company Information
- 12.12.2 Amgen Business Overview
- 12.12.3 Amgen Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.12.4 Amgen Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.12.5 Amgen Recent Developments
- 12.13 AbbVie
- 12.13.1 AbbVie Company Information
- 12.13.2 AbbVie Business Overview
- 12.13.3 AbbVie Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.13.4 AbbVie Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.13.5 AbbVie Recent Developments
- 12.14 AstraZeneca
- 12.14.1 AstraZeneca Company Information
- 12.14.2 AstraZeneca Business Overview
- 12.14.3 AstraZeneca Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.14.4 AstraZeneca Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.14.5 AstraZeneca Recent Developments
- 12.15 Seagen
- 12.15.1 Seagen Company Information
- 12.15.2 Seagen Business Overview
- 12.15.3 Seagen Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.15.4 Seagen Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.15.5 Seagen Recent Developments
- 12.16 Regeneron
- 12.16.1 Regeneron Company Information
- 12.16.2 Regeneron Business Overview
- 12.16.3 Regeneron Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.16.4 Regeneron Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.16.5 Regeneron Recent Developments
- 12.17 Ono Pharmaceutical
- 12.17.1 Ono Pharmaceutical Company Information
- 12.17.2 Ono Pharmaceutical Business Overview
- 12.17.3 Ono Pharmaceutical Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.17.4 Ono Pharmaceutical Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.17.5 Ono Pharmaceutical Recent Developments
- 12.18 Merck & Co
- 12.18.1 Merck & Co Company Information
- 12.18.2 Merck & Co Business Overview
- 12.18.3 Merck & Co Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.18.4 Merck & Co Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.18.5 Merck & Co Recent Developments
- 12.19 Gilead Sciences
- 12.19.1 Gilead Sciences Company Information
- 12.19.2 Gilead Sciences Business Overview
- 12.19.3 Gilead Sciences Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.19.4 Gilead Sciences Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.19.5 Gilead Sciences Recent Developments
- 12.20 Exelixis
- 12.20.1 Exelixis Company Information
- 12.20.2 Exelixis Business Overview
- 12.20.3 Exelixis Revenue in Anti-Neoplastic Pharmaceutical Agent Business (2021-2026)
- 12.20.4 Exelixis Anti-Neoplastic Pharmaceutical Agent Product Portfolio
- 12.20.5 Exelixis Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst